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Abstract
Alcohol use disorders (AUDs) affect approximately 13.9% of the population in the
United States. AUDs result from a combination of biological and environmental factors,
and have a strong genetic component with heritability rates estimated to be 50-60%.
Alcohol consumption has been shown to enhance GABAA receptor activity, and genetic
studies have shown an association between AUDs and single nucleotide
polymorphisms (SNPs) within GABAA receptor subunit genes. Many groups have found
a correlation between AUDs and a synonymous SNP in exon 5 of the GABRA2 gene
(rs279858 T to C; C allele associated with AUDs). However, the biological effects of this
and other SNPs in this region are unknown.
Our lab has been using iPSC technology for the past few years to study AUDs.
The lab has shown, using qPCR of mRNA, that a cluster of GABAA receptor subunit
genes on chromosome 4p12 is expressed at minimal levels in neural cells derived from
half of the iPSC lines (both controls and alcoholics) studied. Expression had a high
correlation to genotype; lines with minimal expression tended to have at least one C
allele of the rs279858 SNP. However, subunits for GABAA receptor subunit genes

located on other chromosomes showed robust expression in all lines. Data from RNAseq of 12-week old iPSC-derived neural cultures showed similar results.
Results generated in this thesis project from chromatin immunoprecipitation
experiments suggest that genetic factors linked to the rs279858 tag-SNP may moderate
the developmental expression of the chromosome 4p12 GABAA receptor subunit gene
cluster by altering epigenetic marks in the promoters of these genes. IPSCs from
expresser lines had epigenetic marks typical of a bivalent promoter (both histone
H3K4Me3 and H3K27Me3 marks present) for GABRA2. During neural development, the
active H3K4Me3 modification remained with a reduction in levels of H3K27Me3 in
neuroepithelial cells and differentiated neural cultures in expresser lines. There were
significantly lower levels of the H3K4Me3 mark in non-expresser iPSCs and neural cell
cultures. In addition, DNA methylation assays looking at a CpG island in the GABRA2
promoter showed that fibroblasts of both expresser and non-expresser lines have very
low CpG DNA methylation. However, after reprogramming, iPSCs from non-expresser
lines show significant amounts of CpG island DNA methylation compared with iPSC
lines which generate chromosome 4p12 GABAA receptor subunit gene expressing
neural cells.
These data suggests that an AUD-linked functional genetic variation may have a
direct influence on epigenetic state of the chromosome 4p12 GABAA receptor subunit
gene cluster and that this effect, while appears very strong in generation of iPSCs, may
have variable effects on epigenetic processes during specific times and brain regions
during neural development.
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Chapter 1.
Introduction

Alcohol Use Disorders
Alcohol use in the United States of America is common as more than 60% of US
adults consume alcoholic beverages regularly. The National Institute of Alcohol Abuse
and Alcoholism (NIAAA) defines moderate drinking as seven drinks per week and no
more than three drinks in a day for women, and 14 drinks per week and no more than
four drinks consumed in a day for men. This moderate alcohol consumption may have
potential beneficial effects as studies have shown that these levels of alcohol use are
associated with reduced the risk of heart disease and stroke (O'Keefe, Bybee et al.
2007), type-2 diabetes (Conigrave, Hu et al. 2001, Djousse, Biggs et al. 2007), and
gallstones (Leitzmann, Giovannucci et al. 1999). However, consuming alcohol in excess
(drinking five or more drinks in a day more than five times in 30 days) can become
hazardous to health and can cause an increase in blood pressure (Maheswaran, Gill et
al. 1991, Husain, Ansari et al. 2014), liver disease (O'Shea, Dasarathy et al. 2010), and
can also increase the risk for various cancers (Boffetta, Hashibe et al. 2006). In
addition, excessive drinking increases the risk of developing an alcohol use disorder
(AUD). The prevalence of AUDs in the US is estimated to be 13.9% (Grant, Goldstein et
al. 2015), meaning approximately one in six adults who drink have some level of an
AUD. This number is slightly higher in men (17.6% 12-month prevalence) than women
(10.4% 12-month prevalence) (Grant, Goldstein et al. 2015). Diagnosis of AUDs is given
according to the criteria in the Diagnostic Statistics Manual version 5 (DSM-5). To be
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diagnosed with an AUD, the patient must meet two or more criteria provided within a 12month period. Briefly, the criteria include: consuming larger amounts of alcohol than
intended, spending a great deal of time drinking, or recovering from drinking, craving
alcohol (a new addition to the DSM-5), failing to fulfill obligations, a persistent desire to
cut down on alcohol intake, giving up activities, continuing the use of alcohol despite
interpersonal problems, acquired tolerance, and withdrawal symptoms. AUD severity
ranges from mild (only meeting two criteria) to severe (meeting six or more criteria). In
addition, AUDs are multifactorial and result from a combination of environmental factors
and complex genetic factors complicating efforts to develop effective treatments even
further. Comparison studies of monozygotic twins and dizygotic twins indicate that
heritability rates of AUDs are 50-60% (Devor and Cloninger 1989, Prescott and Kendler
1999, Goldman, Oroszi et al. 2005, Gelernter and Kranzler 2009). For initiation of use
and early drinking it is thought that environmental effects outweigh genetic risks; an
environment where alcohol is readily available may promote initiation of drinking,
whereas an individual who is never exposed to alcohol will not initiate drinking.
However, genetic effects play a greater role in the transition from moderate drinking to
excessive drinking, alcohol dependence, and AUDs (Gelernter and Kranzler 2009).
Because of the varying levels of severity of AUDs and the complex genetic and
environmental factors, one size fits all treatments have shown limited relief in many
alcoholic subjects (Litten, Egli et al. 2012). In order to develop more effective
treatments, more complete understanding about the biology of AUDs is an important
goal. Because there is a strong genetic component associated with AUDs, it seems a
logical place to explore possible abnormalities and risk factors associated with AUDs.
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The Genetics of AUDs
Genes directly involved with the metabolism of alcohol, including the genes
coding for alcohol dehydrogenase, ADH1B, and aldehyde dehydrogenase, ALDH2,
have been extensively studied in their role of AUD risk (Edenberg 2007). Mutations in
these genes produce an accumulation of acetaldehyde, which results in the drinker
feeling sick. Because of this effect, these mutations are considered to be protective
against AUDs, as carriers of these mutations would generally avoid drinking alcohol and
the associated adverse sensations generated by acetaldehyde.
In addition to these genes, genome-wide association studies (GWAS) looking at
control subjects and alcoholic subjects have provided potential risk genes, including
genes for subunits of GABAA receptors. However, the mechanism behind these variants
is largely unknown. By elucidating the way in which these mutations act, we can provide
more effective and personalized treatments.

GABAA Receptors and AUDs
While the exact mechanism is unknown, acute alcohol exposure is known to
potentiate GABAA receptor activity in the brain (Aguayo 1990). GABAA receptors are
ligand-gated ion channels permeable to chloride and facilitate fast synaptic inhibition.
GABA is the major inhibitory neurotransmitter in the brain and after binding to the
GABAA receptor, induces the potentiation of the ion channel. These ion channels are
pentamers generated by various compositions of 19 different GABAA subunits including
α1-6, β1-3, γ1-3, δ, ε, θ, π, and ρ1-3. The genes encoding the most common subunits
are located on five different chromosomes; chromosome 4p12 harbors γ1, α2, α4, and
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β1; chromosome 5q34 (β2, α6, α1, γ2, and π); chromosome 15q12 (β3, α5, and γ3);
chromosome Xq28 (ε, α3, and θ); and chromosome 1p36 (δ). The structure of the
GABAA receptor and the layout of genes across human chromosomes is shown in
Figure 1.1 (adapted from (Jacob, Moss et al. 2008)). Most commonly, the receptors are
composed of two α subunits, two β subunits, and a γ subunit. However, the subunit
composition for GABAA receptors varies by brain region and differences in subunit
composition create unique electrophysiological and pharmacological properties
(Barnard, Skolnick et al. 1998, Picton and Fisher 2007). The three most common
combinations in the adult brain are α1β2γ2 (60%), α2β3γ2 (15%), and α3β3γ2 (10%)
(Enoch 2008). During development, the subunit composition changes. In rats, primates,
and humans, α1 subunit expression increases with development and α2 expression
decreases showing an importance of the α2 subunit in early development (Laurie,
Wisden et al. 1992, Hashimoto, Nguyen et al. 2009, Fillman, Duncan et al. 2010); a
feature to remember in later discussion.
Numerous studies have shown associations of SNPs in a 140kb region spanning
the 3’ end of GABRA2 and the intergenic region between GABRA2 and GABRG1 to
AUDs (Covault, Gelernter et al. 2004, Edenberg, Dick et al. 2004, Lappalainen,
Krupitsky et al. 2005, Fehr, Sander et al. 2006, Covault, Gelernter et al. 2008, Enoch,
Hodgkinson et al. 2009, Olfson and Bierut 2012). Haplomaps of this area show high
correlations of SNPs within the 140kb haplotype block to expression status of
chromosome 4 GABAA receptor subunit genes in iPSC-derived neural cell culture
versus SNPs outside the haplotype block, which are not associated (Figure 1.2). The
most reproducible studies (see above) have reported an association of AUDs with a
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Figure 1.1. GABAA receptor location of each subunit on their
corresponding chromosomes. GABAA receptors typically
consist of two α subunits, two β subunits, and one γ subunit.
The red bar under chromosome 4p12 indicates the region of
AUD associated SNPS. (Figure adapted from Jacob et al.,
Nature Reviews Neuroscience, 2008)

AUD associated region

p=0.34
rs2351439

*p=0.006
rs573400
rs567926
rs1440133

p=0.33
rs7660336

*p=0.007
rs279858
rs529826
rs534459

p=0.77
rs10028945

α2

140kb haplotype block

Figure 1.2. Diagram of the GABAA receptor subunit gene cluster on chromosome 4p12. The image
shooting out of the chromosome is the 140kb haplotype block diagram generated by Hapmap. The
SNPs with p-values are relative to the association of genotype to iPSC-derived neural cell culture
chromosome 4 GABAA receptor subunit gene expression phenotype. P-values within the box have
strong associations within this region and those outside of the box do not have strong associations.
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synonymous tag-SNP for this region, rs279858, which is located in exon 5 of the
GABRA2 gene and involves a T to C variation; the C-allele being associated with AUD
risk. It has been shown that this AUD risk C-allele has a frequency of 40% in controls
and 46% in alcoholics (Covault, Gelernter et al. 2008). GABRA2 is widespread in early
development and becomes more focalized in adult mice showing the highest expression
in the hippocampus and limbic regions (Pirker, Schwarzer et al. 2000). The GABRA2
alcohol risk allele is also associated with intermediate neural phenotypes such as fast
beta-frequency EEG activity (Edenberg, Dick et al. 2004), activation of the insular cortex
during reward anticipation (Villafuerte, Trucco et al. 2014), changes in activation of the
medial frontal cortex by alcohol cues (Kareken, Liang et al. 2010), and increased
activation of the nucleus accumbens in reward anticipation (Heitzeg, Villafuerte et al.
2014). GABAA receptors containing the α2 subunit mediate the anxiolytic effects of
benzodiazepines, which are used to lessen withdrawal symptoms in alcoholics.
However, the more proximal molecular effects associated with the SNPs in this
haplotype block have yet to be elucidated.

A New Model to Study AUDs
The study of GABAA receptor subunit genes in mice has been highly informative
for the study of human diseases and disorders, including AUDs. The GABAA receptor
subunit genes in mice located on chromosomes 5, 11, 7, X, and 4 are orthologous to the
placement on human chromosomes 4p12, 5q34, 15q12, Xq28, and 1p36, respectively
(Uusi-Oukari, Heikkila et al. 2000). However, while there are many similarities present, a
very important component of AUD risk is SNPs that are specific to the human genome.
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Mouse models have a great ability to show us what happens when full genes are
knocked out, or knocked in, and what the consequences are, but human diseaseassociated genetics are more nuanced than this. So while rodent research has brought
the field a long way in terms of researching basic biological genetics related to AUD risk,
the next leg of research must be catered to the human condition.
One way to study disease associated genetic variants in human tissue is through
iPSC technology. Since 2007 when Takahashi and Yamanaka et al. showed the
reprogramming of human fibroblasts into induced pluripotent stem cells, the use of this
technology has blossomed (Takahashi, Tanabe et al. 2007). Reprogramming is
achieved by introducing four factors (Oct3/4, Sox2, Klf4, and c-Myc) into fibroblasts to
reset cells back to a pluripotent state. One of the greatest difficulties when researching
human neurological disorders and diseases is obtaining viable tissue with which to
perform research. The options were either to mimic the illness in an animal model, or
obtain post-mortem brain tissue. With animal models there is hope the findings are
translatable to humans. However, the ability to translate findings from these approaches
has limitations. It’s been shown that less than 8% of cancer clinical trials have translated
from mice to humans (Mak, Evaniew et al. 2014). One example of these trials that
showed promise in mice, but failed in humans, is the TGN1412 trial. In this trial, all of
the six healthy volunteers who received the TGN1412 monoclonal antibody, which was
supposed to activate T-cells without toxic effects, had multi-organ failure and were
admitted to the hospital (Suntharalingam, Perry et al. 2006). Additionally, all treatments
for amyotrophic lateral sclerosis (ALS) in the last ten years that showed effective results
in mouse models (primarily TDP43 and SOD1 mutants) have failed (or been minimally
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effective) in human trials (Perrin 2014). In terms of post-mortem brain tissue, obtaining
these samples from relevant subjects at early as well as late stages of disease is not
always easy, and when the tissue is obtained the quality and integrity of the cells is
often severely compromised. In addition, post-mortem brain tissue typically only gives a
look at the outcome of the illness at later stages after years of variable treatments and
possible co-morbidities, which is also subject to limitations. IPSC technology has
allowed studies of a number of neurological illnesses at a cellular and molecular level
never before achievable. Studies done with iPSCs and iPSC-derived neurons have
provided insights and advancements in the research of many neurological illnesses
including schizophrenia (Brennand, Simone et al. 2011), bipolar disorder (O'Shea and
McInnis 2015), ALS (Cashman and Lazzerini Ospri 2013, Chen, Qian et al. 2014), and
Prader-Willi and Angelman syndromes (Chamberlain, Chen et al. 2010, Cruvinel,
Budinetz et al. 2014). The use of iPSCs to create live neurons from multiple subjects
carrying defined gene variants, while maintaining the genetic makeup of the subjects,
allows us to choose subjects with and without disease associated variants and study the
possible differences in the neurons associated with these specific human genetic
variants.
Research done in the lab using iPSC-derived forebrain neural cultures has
provided us with some interesting questions regarding the use of iPSCs to study AUDs.
A gene expression analysis using quantitative PCR (qPCR) was done to examine genes
previously associated with AUDs (genes encoding GABAA receptor subunits and NMDA
receptor subunits) in control subjects and alcoholic subjects with different genotypes of
the rs279858 SNP in GABRA2; two T alleles (TT), one T allele and one C allele (TC), or
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two C alleles (CC). When looking at the GABAA receptor genes, it was discovered that
gene expression of a cluster of genes encoding GABAA subunits located on
chromosome 4p12 (GABRG1, GABRA2, GABRA4, GABRB1) was very low in
approximately half of the lines examined. Ten of 11 lines with the TT genotype
expressed this gene cluster (both control and alcoholic subjects), while only four of 14
CC lines expressed the gene cluster, and five of 11 CT lines has the expresser
phenotype. Cluster analysis separated the lines into two groups: lines which express the
GABAA receptor subunit gene cluster on chromosome 4p12, or “expressers,” and lines
which show reduced or minimal expression of the GABAA receptor subunit gene cluster,
or “non-expressers” (Lieberman, Kranzler et al. 2015).
In addition to qPCR data, RNA-seq data was also available for a subset of
samples providing genome wide gene expression data. RNAseq data was used to
calculate correlations between GABAA receptor subunit genes on chromosome 4p12
and other GABAA receptor subunit genes located on other chromosomes. Genes on
chromosome 4p12 were found to be highly correlated, whereas genes on other
chromosomes showed little correlation to GABRA2 (chromosome 4p12). Utilizing this
RNA-seq data, we generated a graph showing the average values of the reads per
kilobase of transcript per million reads mapped (RPKM) for GABAA subunits on
chromosomes 1, 4, 5, 15, and X. In Figure 1.3A, there is a clear difference between the
expresser lines and the non-expresser lines in the gene cluster on chromosome 4p12,
as expected and the non-expresser lines have virtually no expression of these genes.
Figure 1.3B shows that for GABAA subunit genes on other chromosomes there is little
change in expression among expresser lines and non-expresser lines. While these
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Figure 1.3. Graphical representation of RPKM values from RNA-seq data in Lieberman et al.,
2015. (A) Expression of GABAA receptor subunit genes located on chromosome 4p12 in
expressers and non-expressers. Expressers show significantly greater RPKM values than the nonexpressers. (B) Expression of GABAA receptor subunit genes located on chromosomes 5, 15, and
X. Expression does not differ between expressers and non-expressers.
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chromosome 4p12 GABAA receptor subunit genes have low RPKM values in these
cultures (low RPKM values can be unreliable (Mortazavi, Williams et al. 2008)), the
qPCR data in Lieberman et al., 2015 verify the findings from the RNA-seq data and
suggest that what we are seeing is a reproducible phenotype present in ~40% of lines.
Additionally, Lieberman et al., 2015 looked at results from post-mortem tissue
databases and saw no genotype related changes in GABRA2 expression in any of the
samples indicating this could potentially be a developmental phenotype.
Data from the RNA-seq studies in Lieberman et al., 2015, show that the genes
flanking the chromosome 4p12 GABAA receptor subunit gene cluster are expressed
similarly in both expresser and non-expresser lines. Since this phenotype is confined to
the chromosome 4p12 GABAA receptor subunit gene cluster, we have reason to believe
that there is a common regulatory element for this ~1.4mb gene cluster. There is
evidence that this may be a common pattern for clustered GABAA receptor subunit
genes. As mentioned above, the distribution of GABAA receptor subunit genes on the
chromosomes of mice is orthologous to that of humans. In mice it has be demonstrated
that long distance regulation of multiple GABAA receptor subunit genes on chromosome
11 (chromosome 5 in humans) exist. A study done by Uusi-Oukari et al., 2000, found
that α6 -/- mice showed decreased mRNA expression of the β2 and α1 subunits
suggesting a common regulatory element that acts over long distances (Uusi-Oukari,
Heikkila et al. 2000). This finding in mice, together with the orthologous layout of the
GABAA receptor subunit genes on chromosomes, led us to believe we are seeing a
similar mechanism in the human GABAA receptor subunit gene cluster on chromosome
4p12.
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The question remains, what is going on that has linked the genotype of a
synonymous tag-SNP to expression levels of the GABAA receptor subunit genes
clustered on chromosome 4p12 in iPSC-derived neurons? One potential modulator of
this cluster could be a change in epigenetic modifications.

Epigenetic modifications and gene expression
Epigenetics involves mitotically heritable modifications beyond the genomic DNA
sequence. In recent years, the field has been expanding rapidly. What was once
focused on primarily X-linked phenotypes and imprinted genes is now opening into a
world where expression of autosomal genes is found to be heavily influenced by
developmental and environmental, non-genetic features via epigenetic regulation.
In order for DNA to be more compact yet efficiently accessed, it is wrapped
around histone octamers made up of two H2A, two H2B, two H3, and two H4 histone
subunits. Approximately 146bp of double stranded DNA is wrapped around a histone
octamer creating what is called a nucleosome. Each nucleosome is connected by linker
DNA bound to an H1 subunit. The histone subunits each have an N-terminal tail that
can be modified by a number of post-translational modifications including methylation,
acetylation, ubiquitylation, and phosphorylation (Cedar and Bergman 2009). The histone
subunit affected, the location of the residue modified on the tail of the histone subunit,
the type of modification, and the degree of modification can all alter the 3D chromatin
structure and influence the availability of DNA for transcription. For example, the lysine
at position 4 (K4) on the tail of the histone 3 subunit (H3) can be tri-methylated
(H3K4me3) and this mark is seen in up to ~75% of gene promoters and is associated
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with active gene expression (Gu and Lee 2013). Another common histone modification
is the tri-methylation (me3) of lysine 27 (K27) on the histone 3 subunit (H3K27me3).
This mark is associated with repression of transcription. Examples of other lysine
modifications on the histone 3 subunit tail include H3K9me3, a repressive mark found in
differentiated cells, and H3K36me3, a mark found in actively transcribed genes (Zhou,
Goren et al. 2011).
Methylation of histone lysine residues is catalyzed by a number of different
histone methyltransferases (HMTs) also known as “methyl writers” (Ruthenburg, Allis et
al. 2007). H3K4, for example, is methylated by at least 14 known HMTs, all of which
contain a SET (a protein domain characterized in Drosophila: Su(var)3-9, Enhancer of
zeste, Trithorax (Cheng, Collins et al. 2005)) domain. They include: SET1A, SET1B,
SET7/9, MLL1-5, SETMAR, ASH1L, PRDM9, and SMYD1-3 (Gu and Lee 2013). The
SET domains are either related to yeast Set1 and Drosophila Trx as with MLL1-5,
SET1A, and SET1B, or unrelated as with SET7/9, SETMAR, ASH1L, PRDM9, and
SMYD1-3 (Ruthenburg, Allis et al. 2007, Gu and Lee 2013). The SET domain in these
proteins catalyzes the transfer of the methyl group of S-adenosylmethionine to H3K4
(Gu and Lee 2013). In the case of H3K27 methylation, EZH2, which is part of the
polycomb repressive complex 2 (PRC2), initiates methylation (Cedar and Bergman
2009).
Similar to methylation, demethylation of histone lysine residues is not only
dependent on the position of the lysine, but is also sometimes methylation state
specific. For example, Jumonji C (JmjC) domain proteins UTX and JMJD3 are specific
demethylases for di-methylated H3K27 and tri-methylated H3K27 residues, with
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preference for the latter (Swigut and Wysocka 2007). Demethylation of di- and trimethylated H3K4 is initiated by KDM5A-D (Gu and Lee 2013).
Evaluation of histone modification profiles for specific loci is done using
chromatin immunoprecipitation (ChIP) assays, which examines the interaction of
proteins with DNA. For example, ChIP can test to see if a transcription factor interacts
with a promoter of interest, or whether a particular histone modification is enriched in a
given location on the genome. The ChIP process (depicted in Figure 1.4) involves the
cross-linking of histone proteins to DNA with formaldehyde followed by controlled
sonication. The chromatin is then split equally into separate reactions; one for input
(unimmunoprecipitated DNA) and the remaining into different immunoprecipitations with
antibodies to histone proteins of interest (i.e. H3K4me3 or H3K27me3). All samples are
then reverse cross-linked and treated with RNase A and proteinase K, and then the
DNA is purified. The purified DNA from the input sample and IPs are then analyzed via
sequencing or quantitative PCR (qPCR).
Initial research done by Ernst and Kellis in 2010 found 51 annotated chromatin
states in human T-cells using a Hidden Markov Model (Ernst and Kellis 2010). The
following year, Ernst et al. (2011) looked at nine different chromatin marks in nine
different cell types to create regulatory predictions and they defined 15 broad
annotations of chromatin states. The frequency of each chromatin mark was analyzed
and charted to show which annotations best fit each chromatin mark. For example,
H3K4me3 was found to be associated with strong promoters with 99% frequency.
CTCF, a CCCTC-binding protein, was annotated as an insulator with 92% frequency,
and H3K27me3 was associated and annotated as an inactive/poised promoter with 72%
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Figure 1.4. Schematic of the
chromatin immunoprecipitation
assay. Following purification of DNA,
samples can be analyzed by qPCR,
or by sequencing.

frequency (Ernst, Kheradpour et al. 2011). An example of the data from Ernst et al.
2011, is represented in the pink bar at the top of Figure 1.5. This shows that this region
was found to be in a bivalent/poised state in embryonic stem (ES) cells. Additionally,
other archived ChIP-sequencing data on the UCSC Genome Browser (http://
genome.ucsc.edu/) also shows a bivalent/poised promoter for GABRA2 in H1 and H9
ES cells and iPSCs (iPS6.9) (Figure 1.5). A poised promoter has both the active,
H3K4me3, and repressive, H3K27me3, marks present. In the pluripotent state, the gene
is inactive, but poised for expression once its fate has been determined. For example,
differentiated neurons maintain the active mark, and the the enrichment of the
repressive mark decreases in this cell type. The bottom two tracks on Figure 1.5 show
profiles for the active mark and repressive mark in post-mortem mid-frontal lobe brain
tissue in which the bivalent state modifications have resolved (H3K4me3 is relatively
more absent than the H3K27me3); consistent with GABRA2 expression in the brain, the
poised promoter was “switched” to an active promoter.

DNA methylation and CpG islands
Another feature of epigenetic regulation is DNA methylation. While most CpG
sites throughout the genome are methylated, there are regions (typically ~1kb in length)
in the genome with a higher than average GC content, known as CpG islands (Jones
2012), which are typically unmethylated and are found at the promoter of many genes
(Moore, Le et al. 2013). While uncommon, DNA methylation at CpG islands does occur
and is associated with transcriptional silencing and is important in gene regulation and
development (Rose and Klose 2014). In addition, aberrant DNA methylation of cancer
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GABRA2 promoter. The pink bar at the top shows that this region is in a poised state in ES cells (from Ernst et al. 2011 and UCSC Genome
Browser.
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suppresser genes results in a variety of cancers (Cedar and Bergman 2009).
DNA methylation occurs when a methyl group is added to the cytosine ring at
CpG dinucleotides. This process is mediated by a family of DNA methyltransferases
(DNMTs) (Moore, Le et al. 2013). DNMT1 is necessary for the maintenance of DNA
methylation. During DNA replication, DNMT1 methylates the daughter strands in
reference to the parental methylation patterns (Esteller 2007). DNMT1 is crucial for
development, and studies have shown that the knockout of DNMT1 in mice is
embryonically lethal (Li, Bestor et al. 1992). De novo methylation is mediated by
DNMT3A and DNMT3B. While knockout of DNMT3B in mice is embryonically lethal,
DNMT3A knockout mice survive, but typically not more than 4 weeks, (Okano, Bell et
al. 1999).
It is known that there is some opposition between DNA methylation and the
presence of H3K4 methylated histones. DNMT3L, a catalytically inactive DNMT, binds
nucleosomes at the H3 N-terminus and can initiate de novo DNA methylation with the
aid of DNMT3A2 and DNMT3B. However, when H3 is methylated (mono-, di-, tri-) at
lysine 4 (K4), DNMT3L can no longer bind and DNA methylation is inhibited (Ooi, Qiu et
al. 2007).
DNA methylation is ‘read’ by a number of proteins belonging to three separate
families. Methyl-CpG-binding domain (MBD) proteins and zinc-finger domain proteins
generally bind methylated DNA and recruit repressor complexes leading to
transcriptional repression. UHRF (ubiquitin-like containing PHD and RING finger
domain) proteins are important for DNA methylation maintenance as they bind DNMT1,
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which (as mentioned above) aids in DNA methylation maintenance on daughter strands
during replication (Moore, Le et al. 2013).

Thesis Objectives
Hypothesis
Our hypothesis is that a yet-to-be-identified functional SNP represented by the
tag-SNP rs279858 in the 140kb GABRA2 haplotype block is influencing the 1.5mb
chromosome 4p12 GABAA receptor subunit gene cluster through epigenetic
mechanisms including changes in histone modifications and DNA methylation.
Specifically, we hypothesize that the non-expresser neurons are retaining repressive
(H3K27me3) epigenetic marks and/or are losing the activating (H3K4me3) mark during
development. In addition, we hypothesize that the absence of the H3K4me3
modification in these lines allows for DNA methylation of the CpG island located in the
promoters of the GABAA receptor subunit gene cluster on chromosome 4p12.
Alternatively, DNA methylation is inhibiting the ability of histone methyltransferases to
methylate H3K4 in this region.

Aims
1. Compare the histone modification profiles for an active mark, H3K4me3, and a
repressive mark, H3K27me3, in the promoters of the GABAA receptor subunit genes in
iPSC-derived neural cultures that express the chromosome 4p12 gene cluster
(expresser lines) as well as those with reduced expression (non-expressers).
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2. Characterize whether a bivalent “poised” promoter type histone modification
profile is present in iPSCs and whether this differs by neural chromosome 4p12 GABAA
receptor subunit gene cluster expression phenotype.
3. Evaluate and compare DNA methylation profiles at a site in the CpG island in
the promoter of GABRA2, as well as neighboring genes in expresser and non-expresser
iPSC lines.
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Chapter 2.
Histone Modification Profiles in iPSCs and iPSC-derived cells

Background
The process of reprogramming fibroblasts into iPSCs changes epigenetic
features, including histone modifications, chromatin structure, and DNA availability
(Liang and Zhang 2013). To evaluate the potential for epigenetic regulation via changes
in histone methylation on the chromosome 4p12 GABAA receptor subunit gene cluster,
ChIP-seq and ChIP-qPCR were conducted. We used an antibody specific for the
H3K4me3 modification, which is associated with the promoters of active genes, and an
antibody specific for the H3K27me3 modification, which is associated with poised
promoters in pluripotent cells and with facultative heterochromatin and repressed genes
in differentiated cells (Ernst, Kheradpour et al. 2011). Using the UCSC Genome
Broswer, we evaluated archived raw ChIP-seq data tracks for H3K4me3 and
H3K27me3 in ES cells and iPSCs. These tracks, shown in Figure 1.5, were used to
indicate the location of enrichment of our two marks of interest. In pluripotent stem cells,
archived ChIP-seq data indicates the GABRA2 promoter is bivalent, or “poised,”
showing enrichment of both H3K4me3 and H3K27me3 marks, readying the gene to
either be expressed, or repressed during differentiation depending on cell type and
location provided by chemical and developmental cues. In contrast, ChIP-seq tracks
from post-mortem brain mid frontal lobe (BMFL) tissue show decreased H3K27me3
enrichment, and maintenance of the active H3K4me3 mark. Our hypothesis was that
non-expresser lines retain the H3K27me3 repressive enrichment and lose enrichment of
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H3K4me3, the active mark. To assess this, we used ChIP with H3K4me3 followed by
genome wide sequencing to assess and global changes that may be affecting the
cluster of GABAA receptor subunit genes on chromosome 4p12 and ChIP followed by
quantitative PCR (qPCR) to target specific genes/promoters of interest.

Methods
Cell lines
Lines were the same as used in the 2015 Lieberman study (Lieberman, Kranzler
et al. 2015). Briefly, skin punch biopsies were taken from 21 patients and were cultured
as fibroblasts. Fibroblasts were reprogrammed into induced pluripotent stem cells
(iPSCs) by the Stem Cell Core at the University of Connecticut Health Center.

IPSC differentiation into forebrain neurons
Neuronal differentiation was done using the method described in Zeng et al.
(Zeng, Guo et al. 2010). Briefly, iPSCs were cultured on a feeder layer of irradiated
mouse embryonic fibroblasts with human Embryonic Stem Cell Media (hESM)
comprised of DMEM/F12, ß-ME, L-glutamine, Knockout SR, MEM NEAA, and bFGF to
reduce differentiation of colonies. To passage the cells, colonies were treated with 1mg/
ml dispase (in DMEM/F12) for five minutes to loosen attachment to the plate and feeder
cells. Dispase was removed and colonies were washed one time with DMEM/F12.
HESM was added and plates were scraped with a 5ml pipette to break up and release
colonies. A small portion of the colony pieces was passaged to another plate of
irradiated mouse embryonic fibroblasts (iMEFs), and for neuronal differentiation, the
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remaining broken up colonies were transferred to a T-75 suspension flask containing
ESM without bFGF. Stage 1: Medium was changed every day for six days by letting the
cell clusters, also known as embryoid bodies (EBs), settle to the bottom before
removing old medium. Stage 2: On day seven, EBs were spun down at 1,000 rpm for
five minutes and transferred to a new T-75 flask with Neuronal Induction Media (NIM)
containing DMEM/F12, heparin, MEM NEAA, and N2 supplement. EBs were cultured in
NIM for three to four days changing media every other day. Stage 3: EBs were then
plated onto tissue culture treated plates with NIM containing 10% FBS to aid in EB
attachment. Twelve to 14 hours after plating, medium was changed to NIM without FBS,
and then every other day for 10-14 days. Stage 4: Neuroepithelial cell colonies from
plates were dislodged from the plates with a stream of medium from a 1ml pipette and
the detached clusters were transferred to a T-75 suspension flask to culture as
neurospheres. These neurospheres were cultured for seven days in NIM with B27.
Stage 5: Neurospheres greater than 300µm were separated from the other clusters and
dissociated by incubating cells with Accutase for five minutes at 37˚C, spun down, and
then rinsed with Neurobasal medium. Neurospheres were plated on 12-well plates
coated with 20ng/ml laminin. Neurons were cultured in Neuronal Differentiation Medium
(NDM) containing BDNF, GDNF, IGF, laminin, L-glucose, B27, and N2. Medium was
changed every three to four days for 12 weeks, during which time they become
differentiated neurons expressing GABA and glutamate receptor genes. IPSC lines and
iPSC-derived neural cultures from these lines have been previously characterized in our
lab (see Lieberman et al., 2015).
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Chromatin immunoprecipitation (ChIP)
For neurons, ChIP was done using the Millipore EZ-Magna ChIP (17-409)
protocol. For iPSCs and neuroepithelial cells, a combination of multiple protocols was
used including the Millipore EZ-Magna ChIP protocol, a high-throughput ChIP protocol
(Blecher-Gonen, Barnett-Itzhaki et al. 2013), and the Cotney et al. protocol (Cotney and
Noonan 2015). IPSCs from a 10cm petri dish, or neurons from 6-12 24-well wells, were
fixed with a final concentrations of 1% formaldehyde (freshly made) to crosslink
histones to DNA and 1X glycine was then added to quench the excess formaldehyde.
Cells were washed twice with 1X PBS and then a third time with 1X PBS with Protease
Inhibitor Cocktail II (Millipore). Cells were either processed immediately or frozen at
-80˚C until further use. Cells were pelleted at 1,000 rpm for five minutes. Cell pellets
were suspended in 1ml of cell lysis buffer containing 50mM Tris-HCl (pH 8.0), 140mM
NaCl, 1mM EDTA, 10% glycerol, 0.5% NP-40, and 0.25% Triton X-100. Samples were
incubated on ice for 20 minutes. Cells were disrupted using a 2ml Dounc homogenizer
with pestle B (Kontes) for 30 strokes. Lysates were spun down at 2,000g for 5 minutes
at 4˚C and supernatant was discarded. Pellets were resuspended in 300µl nuclear lysis
buffer containing 10mM Tris-HCl (pH 8.0), 1mM EDTA, 0.5mM EGTA, and 0.2% SDS
and incubated on ice for 20 minutes. Chromatin was then sheared into 200-800bp
fragments using controlled sonication with a QSonica sonicator for 30 minutes in 10
second bursts. To evaluate sonication efficiency, 5µl of sonicated material was treated
with RNase A for 30 minutes at 37˚C, followed by a proteinase K treatment at 37˚C and
then reversed crosslinks at 65˚C. The DNA was then run on an agarose gel. The DNA
was a smear localized to 200-800bp. Sonicated material was spun down to remove
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debris and kept at -80˚C until further analysis. Frozen pellets were thawed on ice, and
sheared chromatin was then immunoprecipitated with ChIP-validated antibodies from
Millipore against the active mark, histone 3 tri-methylated lysine 4 (H3K4me3; Millipore,
17-614), and against the repressive mark, histone 3 tri-methylated lysine 27
(H3K27me3; Millipore, 17-622). Antibodies were tested for binding specificity using the
Millipore AbSurance Histone H3 Antibody Specificity Array (Millipore, 16-667).
Antibodies were coupled to washed protein-G magnetic beads (Millipore, 16-662) in
blocking binding buffer containing 1% BSA and 1% Tween-20 in PBS in low-bind 1.5ml
tubes and incubated at room temperature for one hour. Beads were then separated
from the buffer using a magnetic rack. The supernatant was discarded and the beads
were resuspended in a portion of sonicated material diluted to 500µl with dilution buffer
consisting of 0.01% SDS, 1.1% Triton X-100, 1.2mM EDTA, 16.7mM Tris-HCl, 167mM
NaCl, and protease inhibitor cocktail II (Millipore, 539132). Samples were incubated
overnight at 4˚C on a rotator. The following day, beads were separated using the
magnetic rack and the supernatant was discarded. The beads were resuspended in
180µl dilution buffer with protease inhibitors and transferred to a well in a pre-chilled 96well PCR plate. Beads were separated using a magnetic rack for 96-well plates and the
supernatant was discarded. Beads were washed with 180µl cold Low Salt Immune
Complex Wash Buffer (Millipore, 20-154) twice, 180µl High Salt Immune Complex Wash
Buffer (Millipore, 20-155) twice, LiCl Immune Complex Wash Buffer (Millipore, 20-156)
twice, and TE buffer (Millipore, 20-157). Beads were washed by moving the plate from
side to side on the magnetic rack. After the removal of the TE buffer, beads were
resuspended in 50µl elution buffer consisting of 10 mM Tris-HCl (pH 8.0), 5 mM EDTA
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(pH 8.0), 300 mM NaCl, and 0.5% SDS. Samples were treated with 1µg RNase A for 30
minutes at 37˚C and then proteinase K treated for 2 hours at 37˚C followed by a 65˚C
incubation overnight. The following day, beads were separated using the magnetic rack
and the supernatant was moved to a new plate. To purify the DNA, Agencourt AMPure
XP beads (Beckman Coulter, A63881) were added at 2.3x the volume of supernatant
and mixed by pipetting up and down 25 times. Samples were incubated at room
temperature for 2 minutes and then the beads were allowed to be separated using the
magnetic rack for 4 minutes. Supernatant was removed and beads were washed twice
with 100µl 70% EtOH for 30 seconds while the plate remained on the rack. After all of
the ethanol was removed the plate was removed from the rack. The beads were dried at
room temperature for 4 minutes. Beads were then resuspended in 60µl 10mM Tris-HCl
(pH 8.0) and mixed by pipetting up and down 25x. Samples were incubated at room
temperature for 2 minutes. The plate was returned to the rack for 4 minutes to separate
out the beads and the supernatant was transferred to another plate.
The concentration of ChIP DNA was measured using the Qubit dsDNA High
Sensitivity Assay Kit (Thermo Fisher Scientific, Q32851). ChIP DNA was then used to
construct sequencing libraries (undiluted), or diluted to 50pg/µl for qPCR.

ChIP-seq
ChIP was done with both iPSCs and iPSC-derived neuroepithelial cells from both
an expresser line, 563-9, and a non-expresser line, 559-5, and immunoprecipitated with
H3K4me3. Resulting ChIP-DNA from the immunoprecipitations, as well as inputs for
each cell type (563-9 iPSC, 563-9 neuroepithelial cells, 559-5 iPSCs, and 559-5
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neuroepithelial cells), was then processed using the Illumina TruSeq ChIP Sample
Preparation protocol. Briefly, End Repair was done on 50µl of 100-200pg/µl ChIP or
input DNA to blunt the ends by removing 3’ overhangs and filling in 5’ overhangs. Next
the 3’ ends were adenylated to prevent fragments from ligating to one another in the
next step where multiple indexing adaptors are ligated to the DNA fragments for
hybridization. The ligation products were run on an agarose gel, the region of the gel
containing DNA in the 200-350bp size-range was excised, and DNA was extracted
using a gel extraction kit (Qiagen, 28704). DNA was examined using a TapeStation
instrument (Agilent) to confirm DNA fragments were in the 250-300bp size-range, which
is optimal for efficient cluster generation. The purified adapter modified DNA products
were amplified using PCR. The ChIP DNA target size range was validated again using
the TapeStation and the library DNA was quantified using the NEBNext Quant Kit for
Illumina (New England Biolabs, E7630S). The DNA library samples were normalized
and pooled for sequencing using the Illumina NextSeq 500 system with a High Output
Kit (75 cycles; Illumina, FC-404-1005).
ChIP-seq data was analyzed first by SICKLE for adaptive trimming of the reads
to remove poor quality ends. Reads were aligned to the genome (hg19) using STAR.
HOMER was then used to create bedGraph files to import into the UCSC Genome
Browser to view raw data pile-up tracks, find peak calls, annotate peaks, and create a
meta-gene for each line. DiffBind was used to contrast peaks between samples with
ChIP-seq data.
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Quantitative real-time PCR for ChIP
To obtain multiple primers specific for the GABAA receptor subunit genes’
promoter regions, the target genome sequence 1000 bases upstream of each gene
(guided from archived ChIP-seq data from the UCSC genome browser) was entered
into PCR Tiler (http://pcrtiler.alaingervais.org:8080/PCRTiler/), which calculates primer
pairs with specified annealing temperatures, GC content, and product specificity.
Primers were designed for the GABRA2 (gene of interest; chromosome 4) promoter,
GABRB2 (chromosome 5) promoter as a comparative control, GUF1 (a gene flanking
the chromosome 4 cluster) as another comparative control, a region negative for both
H3K4me3 and H3K27me3 enrichment near GABRA2 (negative control), and MYOD1 (a
positive control for H3K27me3 enrichment). A positive control for H3K4me3 enrichment
were the control primers for GAPDH, supplied with the ChIP antibody. For primer
sequences, see Table 2.1. QPCR was done in duplicate using 20µl reactions with 1µl
50pg ChIP DNA, primers, and SYBR Green Master Mix (Thermo Fisher Scientific,
4309155). QPCR was conducted using an ABI 7500 PCR System. The protocol was
95˚C for 10 minutes, and 40 cycles of 95˚C for 15 seconds and 60˚C for 1 minute. To
calculate fold over input, the average Ct values of duplicates were calculated and then
entered into the equation: 2(Input Ct average – IP Ct average). Fold enrichments were compared
between groups using a 2-tailed student’s t-test.

Results
To assess possible differences in histone modification enrichment between
expresser and non-expresser lines, we examined 12- to 15-week (post plating) neural
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Primer
ChpGA2_C Forward
ChpGA2_C Reverse
GAPDH Forward
GAPDH Reverse
MYOD1 Forward
MYOD1 Reverse
ChpGB2_B Forward
ChpGB2_B Reverse
GUF1 Forward
GUF1 Reverse
Negative control Forward
Negative control Reverse

Target
GABRA2
GAPDH
MYOD1

Sequence (5'-3')
CTC CCA AGT TTC CTA TCT CGT CAA

Tm (˚C)

AGT GTC TCT ATC GGG ACC AAC G

58.2

TAC TAG CGG TTT TAC GGG CG

57.2

TCG AAC AGG AGG AGC AGA GAG CGA

63.3

CGC CAG GAT ATG GAG CTA CT

56.2

CGG GTC GTC ATA GAA GTC GT

56.3

CTC TGG GTG TGC GAG TCC

58.1

CGG AGC GGT CCC TAG AAG

57.3

GGC TAC CGA CAG GCT CTA

56.1

GCC CTA TAC ATG TCC AAG ATC G

55

TGA GGC TAG AGG GTA TAA AGT G

53.3

ACT GGT AAC CAA CTT CAA ACA A

52.7

GABRB2
GUF1
Unenriched
region in
GABRA2

Tabel 2.1. Primer sequences and melting temperatures for ChIP-qPCR.
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56.2

cultures of previously identified lines from Lieberman et al. 2015. Using archived ChIPseq data tracks from the Genome Browser, we targeted the sequence of the promoter
region of GABRA2 using PCR tiler to obtain primers that coincided with the H3K4me3
and H3K27me3 peaks. Histone modification enrichment was analyzed by ChIP-qPCR
using antibodies to H3K4me3 and H3K27me3, and data was measured as a percent of
the input DNA. We found that the active mark, H3K4me3, was robustly enriched at the
GABRA2 promoter in expresser neural cultures (n=7), but not in non-expresser lines
(n=4) (Figure 2.1A, *p=0.02). The repressive mark, H3K27me3, showed no significant
difference between expresser (n=6) and non-expresser (n=2) neurons (Figure 2.1B,
p=0.7). GAPDH, a housekeeping gene, was used as a positive control for H3K4me3
enrichment and showed no significant difference between expresser (n=7) and nonexpresser (n=4) lines (Figure 2.1C, p=0.1). The GAPDH promoter, which is a strong
promoter, had no enrichment of H3K27me3 in either expressers (n=6) or nonexpressers (n=2) as expected (Figure 2.1D, p=0.25). This suggested a link between
expression status and H3K4me3 enrichment in neurons.

ChIP-seq to evaluate genome wide enrichment of H3K4me3
Messenger RNA (mRNA) expression timelines were previously done in the lab
looking at GABRA1 and GABRG2, located on chromosome 5, and GABRA2 and
GABRG1, located on chromosome 4p12. Expression data from two TT lines
(expressers) and two CC lines (non-expressers) from iPSCs, neuroepithelial cells (NE),
and neural cell cultures 2-, 6-, and 15-weeks (post-plating). mRNA expression data for
genes located on chromosome 5, GABRA1 and GABRG2, show no expression in
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Figure 2.1. ChIP-qPCR data for expresser and non-expresser 12-15 week iPSC-derived neurons. (A)
H3K4me3 enrichment at the GABRA2 promoter (expressers n=7 and non-expressers n=4; *p=0.02).
(B) H3K27me3 enrichment at the GABRA2 promoter (expressers n=6 and non-expressers n=2;
p=0.74). (C) H3K4me3 enrichment at the GAPDH promoter (expressers n=7 and non-expressers n=4;
p=0.1). (D) H3K27me3 enrichment at the GAPDH promoter (expressers n=7 and non-expressers n=4;
p=0.25).
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iPSCs and NE, but begin to show low expression in 2-week neural cell cultures (Figure
2.2A, B) in both TT (blue) and CC (red) lines, and robust expression in 15-week neural
cell cultures. However, expression of GABRA2 and GABRG1 shows differences
between TT and CC lines starting in 2-week neural cell cultures (Figure 2.2C, D);
expression in the TT lines progresses, but the CC lines show no expression for all timepoints. As epigenetic changes precede gene expression, and because we saw
differences in expression levels as early as in 2-week neural cell cultures, we predicted
that there could be different histone modification profiles for expresser and nonexpresser lines as early as at the neuroepithelial cell (NE) state. Knowing pluripotent
cells (hESC lines H1 and H9, and iPSC line 6.9) have bivalent/poised promoters (see
Figure 1.5), we set out to find when the switch from the poised promoter to a resolved
active promoter occurs during differentiation.
First, to get a genome-wide perspective of H3K4me3 enrichment to see if there
was reduction in H3K4me3 enrichment selectively in the chromosome 4p12 GABAA
receptor subunit gene cluster in non-expresser lines, we performed ChIP followed by
whole genome sequencing on iPSCs (one expresser and one non-expresser line) and
neuroepithelial cells (one expresser and one non-expresser). A ChIP library was made
using H3K4me3 IP DNA and input DNA and run on a NextSeq instrument. Analysis of
the data was done using the program SICKLE first to trim low quality ends, STAR to
align to the hg19 genome, and then Homer to create bedGraph files, obtain peak calls,
annotate peaks, and create meta-gene profiles. Files were uploaded to the UCSC
Genome Browser to visualize pile-up maps of the raw ChIP-seq data peaks and the
peak calls. The distribution of peak calls is shown in Figure 2.3 for each line. Each pie
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Figure 2.2. mRNA expression time course of GABAA receptor subunit genes in expresser (TT) (n=2)
and non-expresser (C-carrier) (n=2) lines. (A) Expression of two genes, GABRA1 and GABRG2,
located on chromosome 5q34. Both non-expresser and expresser lines show expression in neurons.
(B) Expression of two genes, GABRA2 and GABRG1, located on chromosome 4p12. Expression
begins in two week neurons in expresser lines, but non-expressers never express either gene up to 15
week neurons.
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Figure 2.3. Distribution of H3K4me3 peaks from ChIP-seq. (A-D) Experimental lines. (E,F)
Data from Genome Browser archive for comparison.
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chart shows the percentage of peaks within exons, introns, intergenic regions,
promoters, 5’ UTRs, and an ‘other’ group for the remaining peaks. Archived data from
the Genome Browser for H1 ES cells and iPSC 6.9 were analyzed to create pie charts
to use as a comparison to our samples and show similar profiles indicating our ChIPseq was successful. Additionally, the distribution of alignments were nearly identical
between samples. The meta-gene profile for each line is shown in Figure 2.4 showing
similar distribution of ChIP-seq alignment along a meta-gene and a peak at the
transcript start site. All genes are scaled to be 10,000bp (gene linear distance
equivalent of 0% to 100%) with 5,000bp upstream and downstream of the gene (Figure
2.4 A-D). Again, archived data from the Genome Browser for H1 ES cells and iPSC 6.9
(Figure 2.4 E, F) were used for comparison and showed similar profiles to our samples,
again validating our ChIP-seq protocol.
Pile-up maps of raw ChIP-seq data and the peak calls visualized in the UCSC
genome browser show robust enrichment of H3K4me3 in a pluripotent-associated gene,
NANOG, in both expresser and non-expresser iPSC lines, but as expected, not in the
iPSC-derived neuroepithelial cells from either line (data not shown). In contrast, there
was robust enrichment of H3K4me3 in a neuronal frontal cortex-associated gene,
FOXG1, in the neuroepithelial cells, but not in the iPSCs (data not shown). These
results further validate the ChIP-seq datasets.
At the GABRA2 promoter, there is enrichment of H3K4me3 in expresser iPSCs
and iPSC-derived neuroepithelial cells, but not in the non-expresser neuroepithelial cells
and unexpectedly also in the non-expresser iPSC sample (Figure 2.5). To see if this
difference between expresser and non-expresser lines was present in the other
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Figure 2.4. Meta-gene profiles for (A) expresser iPSC, (B) expresser neuroepithelial cells, (C) nonexpresser iPSCs, and (D) non-expresser neuroepithelial cells. H1 (E) and iPSC 6.9 (F) were used for
comparison. All genes are scaled to 10,000bp (equal to 100%) with 5,000bp upstream and downstream
of the gene included.
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Figure 2.5. Raw ChIP-seq data tracks (green peaks) and peak calls (black bars) showing enrichment of H3K4me3 at the GABRA2 promoter in
an iPSC expresser, neuroepithelial cell expresser, iPSC non-expresser, and neuroepithelial cell non-expresser.

Nonexpresser

Expresser

GABRA2

chromosome 4p12 GABAA receptor subunit genes, enrichment of H3K4me3 was
examined in the promoters of GABRG1, GABRA4, and GABRB1 (Figure 2.6A-C).
Similar to GABRA2, enrichment of H3K4me3 in expresser iPSCs and iPSC-derived
neuroepithelial cells was significantly higher at these promoters than enrichment in nonexpresser iPSCs and iPSC-derived neuroepithelial cells.
We also assessed the flanking genes of the GABAA receptor subunit gene cluster
on chromosome 4p12. GUF1, GNPDA2, and COMMD8 all showed robust expression in
all lines (Figure 2.7A-C).
When comparing peak calls between GABAA receptor subunit gene clusters on
different chromosomes, there were no significant differences between the expresser or
the non-expresser line in these clusters as there was with the chromosome 4p12 cluster
(data not shown).
To contrast peaks in the ChIP-seq data, the application DiffBind was used. The
number of H3K4me3 binding regions in the four samples was 21,032. When contrasting
samples by expresser and non-expresser lines, there were 46 regions that were
significantly different at a false discovery rate (FDR) <0.01 including the four GABAA
receptor subunit genes clustered at chromosome 4p12 (see Table 2.2 for full list).
Contrasting iPSC and neuroepithelial cell samples, there were 5,960 significant
differences found at a FDR <0.01 reflecting the large change in the enrichment
distribution of this epigenetic mark associated with the differentiation process.

39

40

Expresser

GABRB1

Non-expresser

Expresser

GABRA4

Non-expresser

Expresser

GABRG1

iPSCs
Neuroepithelial cells

iPSCs
Neuroepithelial cells

iPSCs
Neuroepithelial cells

iPSCs
Neuroepithelial cells

iPSCs
Neuroepithelial cells

iPSCs
Neuroepithelial cells
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receptor subunit gene cluster. Graphs show enrichment at the (A) GABRG1 promoter (B) GABRA4 promoter, and (C) GABRB1 promoter in an
iPSC expresser, neuroepithelial cell expresser, iPSC non-expresser, and neuroepithelial cell non-expresser.
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Figure 2.7. Peak calls (black bars) showing enrichment of H3K4me3 at promoters of genes flanking the chromosome 4p12 GABAA receptor
subunit gene cluster. Graphs show enrichment at the (A) COMMD8 promoter (B) GNPDA2 promoter, and (C) GUF1 promoter in expresser
iPSCs, expresser neuroepithelial cells, non-expresser iPSCs, and non-expresser neuroepithelial cells.
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A

Gene Name

Gene Description

Chromosome

ACOT1
ANKRD20A5P
BMS1P5
CHCHD2
CNTNAP3
COL22A1
CRYZ
EIF3CL
FAM86B3P
GABRA2
GABRA4
GABRA5
GABRB1
GABRG1
GRM7
HKR1
HLA-C
HLA-DQB1
HLA-DRB1
LINC01060
LINC01194
LOC100287846
LOC101927815
LOC101927815
LOC101927815
LYNX1
NEUROD4
NLRP2
NNAT
PARG
PHACTR3
PHACTR3
PLS3
PNRC2
SEPT7P9
SLURP1
SRSF10
STAG3L2
THEM6
TRIM43
TRPC7
TTTY3
TULP1
ZNF132
ZNF558
ZSCAN23

acyl-CoA thioesterase 1
ankyrin repeat domain 20 family, member A5, pseudogene
BMS1 pseudogene 5
coiled-coil-helix-coiled-coil-helix domain containing 2
contactin associated protein-like 3
collagen, type XXII, alpha 1
crystallin, zeta (quinone reductase)
eukaryotic translation initiation factor 3, subunit C-like
family with sequence similarity 86, member A pseudogene
gamma-aminobutyric acid (GABA) A receptor, alpha 2
gamma-aminobutyric acid (GABA) A receptor, alpha 4
gamma-aminobutyric acid (GABA) A receptor, alpha 5
gamma-aminobutyric acid (GABA) A receptor, beta 1
gamma-aminobutyric acid (GABA) A receptor, gamma 1
glutamate receptor, metabotropic 7
HKR1, GLI-Kruppel zinc finger family member
major histocompatibility complex, class I, C
major histocompatibility complex, class II, DQ beta 1
major histocompatibility complex, class II, DR beta 1
long intergenic non-protein coding RNA 1060
long intergenic non-protein coding RNA 1194
patched 1 pseudogene
uncharacterized LOC101927815
uncharacterized LOC101927815
uncharacterized LOC101927815
Ly6/neurotoxin 1
neuronal differentiation 4
NLR family, pyrin domain containing 2
neuronatin
poly (ADP-ribose) glycohydrolase
phosphatase and actin regulator 3
phosphatase and actin regulator 3
plastin 3
proline-rich nuclear receptor coactivator 2
septin 7 pseudogene 9
secreted LY6/PLAUR domain containing 1
serine/arginine-rich splicing factor 10
stromal antigen 3-like 2 (pseudogene)
thioesterase superfamily member 6
tripartite motif containing 43
transient receptor potential cation channel, subfamily C, member
testis-specific transcript, Y-linked 3 (non-protein coding)
tubby like protein 1
zinc finger protein 132
zinc finger protein 558
zinc finger and SCAN domain containing 23

chr14
chr18
chr10
chr7
chr9
chr8
chr1
chr16
chr8
chr4
chr4
chr15
chr4
chr4
chr3
chr19
chr6
chr6
chr6
chr4
chr5
chr8
chr8
chr8
chr8
chr8
chr12
chr19
chr20
chr10
chr20
chr20
chrX
chr1
chr10
chr8
chr1
chr7
chr8
chr2
chr5
chrY
chr6
chr19
chr19
chr6

Table 2.2. DiffBind regions significantly different at a false discovery rate (FDR) <0.01
including the chromosome 4p12 GABAA receptor subunit genes (highlighted in orange).
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Validating ChIP-seq with ChIP-PCR
ChIP-qPCR was first done in iPSCs to evaluate the presence or absence of a
bivalent promoter state in our cell lines as the ChIP-seq data showed a lack of
H3K4me3 enrichment in the non-expresser line. In these experiments, primers targeting
the promoter of GABRA2 were used, primers targeting the promoter of GABRB2 were
used to evaluate enrichment in a GABAA receptor subunit gene located on a different
chromosome (chromosome 5), and primers targeting the promoter of GUF1, a flanking
gene of the chromosome 4p12 GABAA receptor subunit gene cluster shown to have
mRNA expression in both expresser and non-expresser lines. A negative control
targeting a region within the GABRA2 gene lacking enrichment of H3K4me3 and
H3K27me3 (based on archived ChIP-seq data (see Figure 1.5)) was also examined.
After qPCR with the GABRA2 promoter region primers, we found that expresser iPSC
lines showed robust enrichment of the active H3K4me3 mark and low, but present,
enrichment of the repressive H3K27me3 mark (Figure 2.8A, B). However, the nonexpresser iPSC lines, while showing some enrichment of the repressive H3K27me3
mark, showed significantly less enrichment of the active H3K4me3 mark compared to
the expresser lines (Figure 2.8A, B) consistent with the ChIP-seq findings. This
suggests that the promoter of the non-expresser cells was in fact never poised in iPSCs
as there is a lack of H3K4me3 enrichment, and that the differences in mRNA expression
fate between lines seen in neural cell cultures may be set not during neural
differentiation, but in iPSCs.
To examine whether the differences seen between the iPSCs in the two
expression groups were specific to the chromosome 4p12 GABAA receptor subunit
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Figure 2.8. Enrichment of histone modifications in expresser and non-expresser iPSCs. (A)
H3K4me3 enrichment at the GABRA2 promoter (expresser n=7 and non-expresser n=4; **p=0.01).
(B) H3K27me3 enrichment at the GABRA2 promoter (expresser n=7 and non-expresser n=4;
p=0.24). (C) H3K4me3 enrichment at the GABRB2 promoter (expresser n=6 and non-expresser
n=4; p=0.65). (D) H3K27me3 enrichment at the GABRB2 promoter (expresser n=5 and nonexpresser n=4; p=0.74). (E) H3K4me3 enrichment at the GUF1 promoter (expresser n=7 and nonexpresser n=3; p=0.83). (F) H3K27me3 enrichment at the GUF1 promoter (expresser n=7 and nonexpresser n=4; p=0.42).
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gene cluster, we examined the promoter of GABRB2, a GABAA receptor subunit gene
located on chromosome 5. Enrichment of H3K4me3 was robust in both expresser and
non-expresser lines, with no significant difference between the two groups (Figure
2.8C, D). In addition, H3K27me3 enrichment was robust in both groups indicating that
this gene promoter is in a poised promoter state in iPSCs with no significant difference
between expressers and non-expresser lines (Figure 2.8C, D).
As mentioned in Chapter 1, Lieberman et al. (2015) discovered that the genes
flanking the chromosome 4p12 GABAA receptor subunit gene cluster were expressed in
neural cell cultures derived from both expresser and non-expresser lines indicating that
transcriptional repression in this region is localized to the GABAA receptor subunit gene
cluster in non-expressers. Because of this, we evaluated the histone modification
enrichment at the promoter of GUF1, a flanking gene downstream of GABRG1. This
showed a strong promoter with high H3K4me3 enrichment, but no H3K27me3
enrichment and with no difference seen between the expressers and non-expressers at
this site (Figure 2.8E, F) consistent with the gene expression data (Lieberman, Kranzler
et al. 2015). To measure background enrichment, a region within GABRA2 that was
unenriched (based on the Genome Browser data in Figure 1.5) was used as a negative
control. As expected, both H3K4me3 and H3K27me3 enrichment was very low in both
expresser and non-expresser lines (Figure 2.9A, B). GAPDH was used as a positive
control for H3K4me3 enrichment showing robust enrichment in both expressers and
non-expressers (Figure 2.9C, D), and MYOD1 was used as a positive control for
H3K27me3 enrichment showing robust enrichment in both expressers and nonexpressers (Figure 2.9E, F).
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Figure 2.9. Enrichment of histone modifications in expresser and non-expresser iPSCs. (A)
H3K4me3 enrichment at the GABRA2 unenriched negative control (expresser n=7 and nonexpresser n=4; p=0.68). (B) H3K27me3 enrichment at the GABRA2 unenriched negative control
(expresser n=7 and non-expresser n=4; p=0.3). (C) H3K4me3 enrichment at the GAPDH promoter
(expresser n=6 and non-expresser n=4; p=0.42). (D) H3K27me3 enrichment at the GAPDH
promoter (expresser n=6 and non-expresser n=4; p=0.25). (E) H3K4me3 enrichment at the MYOD1
promoter (expresser n=6 and non-expresser n=4; p=0.71). (F) H3K27me3 enrichment at the
MYOD1 promoter (expresser n=5 and non-expresser n=4; p=0.52).
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Discussion
Based on archived ChIP-seq data from the UCSC Genome Browser from H1 and
H9 embryonic stem cell and iPSC 6.9 tracks (Figure 1.5) and the data from Ernst et al.,
2011, we expected to see a basal poised/bivalent H3K4me3 and H3K27me3 epigenetic
state at the GABRA2 gene promoter in all iPSC lines followed by divergence of
epigenetic marks reflecting gene expression status after beginning neural differentiation.
However, we found that there is a difference in expresser and non-expresser lines
already in iPSCs. While expresser lines showed enriched H3K4me3 and H3K27me3
marks, the non-expresser lines showed significantly less enrichment of the H3K4me3
mark, but showed similar levels of H3K27me3 enrichment as the expresser lines.
As there were significant differences of H3K4me3 enrichment between the
expresser and non-expresser lines in the ChIP-seq experiments, it would be interesting
to get a genome wide evaluation of H3K27me3 enrichment in expresser and nonexpresser iPSCs. It was hard to tell in the qPCR experiments if there was much
H3K27me3 enrichment in the non-expresser lines and having this additional ChIP-seq
data may help give a comprehensive view of H3K4me3 versus H3K27me3
modifications in the chromosome 4p12 receptor subunit gene cluster region.
Additionally, as mentioned in Chapter 1, the H3K27me3 mark is regulated by the
polycomb repressive complex 2 (PRC2) and is normally associated with poised
promoters and pluripotent cells. During differentiation if the gene is to be repressed, the
H3K27me3 mark is replaced with H3K9me3, which is associated with gene repression
in differentiated cells. It would be interesting to see if the non-expresser lines show
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replacement of H3K27me3 with H3K9me3 in iPSCs or neuroepithelial cells in response
to this yet-to-be identified functional variant.
The limited H3K4me3 enrichment in the GABRA2 promoter in the non-expresser
iPSC lines observed in our ChIP-seq and ChIP-qPCR datasets suggests that epigenetic
reprogramming during iPSC generation is targeting the chromosome 4p12 receptor
subunit gene cluster for inhibition in non-expresser lines. It is possible that this region in
non-expressers acquires another repressive epigenetic mark that is impacting the ability
of H3K4 methyltransferases to methylate K4. Another possibility, discussed in Chapter
3, is that there is differential DNA methylation at the CpG islands in the promoters of the
chromosome 4p12 GABAA receptor subunit genes between expresser and nonexpresser lines and this is inhibiting transcription activation.
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Chapter 3.
DNA Methylation of GABAA Receptor Subunit Genes

Background
DNA methylation is a common epigenetic modification that can be altered when
reprogramming fibroblasts to iPSCs. It is also known that there is a strong relationship
between DNA methylation and histone modifications. In early development, CpG islands
are typically unmethylated. This is perhaps due to the presence of methylation of the
lysine 4 residue on the H3 tail (H3K4me). DNMT3L, a catalytically inactive binding
partner of DNMT3A2 and DNMT3B, initiates the interaction between chromatin and the
DNMT complex. It does this by recognizing the K4 residue on the H3 subunit tail.
However, when H3K4 is methylated, it blocks the ability for DNMTL to bind inhibiting
DNA methylation at this site. Thus, there is a negative correlation between methylation
of H3K4 (associated with activation of genes) and DNA methylation of CpG islands
(associated with gene repression). In addition, DNA methylation has been linked to
H3K27me3, a mark associated with gene repression. It has been suggested that DNA
methylation of CpG islands at promoters during differentiation is more likely if the
promoter is marked with H3K27me3 in embryonic stem cells (Cedar and Bergman
2009, Rose and Klose 2014).
A study done in Bulgaria looking at genome-wide methylation profiles in
schizophrenia found DNA hypermethylation of the CpG island in the GABRA2 promoter
in male schizophrenic subjects (Rukova, Staneva et al. 2014). In addition, a study
looking at DNA methylation in aging, a progressive increase in DNA methylation of the
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GABRA2 CpG island over the lifespan was observed in men (Siegmund, Connor et al.
2007). These studies suggest that differential DNA methylation of the GABRA2
promoter CpG island could be a possible explanation for the two gene expression
phenotypes we observe. Based on these studies and the ChIP findings in Chapter 2, we
set out to evaluate a possible link between reprogramming fibroblasts into iPSCs and
DNA methylation states of the GABRA2 promoter CpG island, as well as the link to
chromosome 4p12 GABAA receptor subunit gene cluster expression status. We
hypothesize that the fibroblast cells will have DNA methylation present at the GABRA2
promoter CpG island which are reset to an unmethylated state in GABAA receptor
subunit gene cluster expresser lines but remain methylated in non-expresser lines.

Methods
Cell lines
Lines were the same as used in the 2015 Lieberman study (Lieberman, Kranzler
et al. 2015). Briefly, skin punch biopsies were taken from 21 patients and were used to
generate fibroblast cell lines. Fibroblasts were reprogrammed into induced pluripotent
stem cells (iPSCs) by the Stem Cell Core at the University of Connecticut Health
Center. This study utilized 24 expresser lines from 17 subjects and 15 non-expresser
lines from 11 subjects to measure DNA methylation at the CpG island in GABRA2. For
targeting GABRA4 promoter CpG island DNA methylation, eight expresser lines lines
from six subjects, and seven non-expresser lines from seven subjects were examined.
For GABRB1, five expresser lines from four subjects, and five non-expresser lines from
five subjects were examined. A gene flanking the GABAA receptor subunit gene cluster,
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GNPDA2, whose RNA levels are not linked to the cluster expression pattern, was
examined using two expresser lines from two subjects and three non-expresser lines
from three subjects.

DNA methylation assay
Evaluation of DNA methylation was done using a combination of the method in
Holemon et al. (Holemon, Korshunova et al. 2007) and the Qiagen Epitect Methyl-qPCR
protocol. Briefly, 250ng of fibroblast, or iPSC DNA was split into four tubes: mockenzyme (Mo), a CpG methylation sensitive (Ms) enzyme, HhaI

(New England

Biosystems), a CpG methylation dependent (Md) enzyme McrBC (New England
Biosystems), and a double enzyme mix with both HhaI and McrBC (Msd). Samples
were incubated overnight at 37˚C. Digested DNA was then analyzed by qPCR using
2

primers for a site within the GABRA2 promoter CpG island (Figure 3.1) using the RT

SYBR Green ROX qPCR Mastermix (Qiagen), a master mix designed for high GC
content products. In addition, primer sets were designed for a site within the CpG
islands in the promoters of GABRA4, GABRB1, and GNPDA2 (Table 3.1). The qPCR
amplification protocol was 95˚C for 10 minutes, 3 cycles of 99˚C for 30 seconds and
72˚C for 1 minute, and 40 cycles of 97˚C for 15 seconds and 72˚C for 1 minute. A
dissociation curve was included at the end of the protocol to monitor melting curves for
single melt peaks. Resulting Ct values for Mo, Ms, Md, and Msd were then entered into
an Excel spreadsheet (www.sabiosciences.com/dna_methylation_data_analysis.php),
that calculates digestion efficiency by giving an analytical window (W) and the
percentage of DNA refractory (R) to restriction enzyme digestion, and also the
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Figure 3.1. CpG island in the GABRA2 promoter (green bar). The dots below represent HhaI (methylation sensitive) restriction
enzyme sites within the CpG island. The black bar at the bottom marks the amplicon of interest used to assay methylation status
in GABRA2.

PCR amplicon

HhaI sites

CpG island

GABRA2

Primer

Target

Sequence (5'-3')

Tm (˚C)

GA2CpG Forward v2

CpG island in the
promoter of GABRA2

CTCGATCCCTCGATCCCTGGTAACT

61.2

CGCCACACTACATTCCCGGCTTTA

61.3

CpG island in the
promoter of GABRA4

CAGGGTGCGAGGAGAGGGC

63.1

ACGAAAGGGTGTGGAGCGGT

61.7

CpG island in the
promoter of GABRB1

TCTGCGTTTCATTGGCGGTCAC

60.5

GGCAGGGCCTTGGTGCAT

61.7

CpG island in the
promoter
of GNPDA2
GNPDA2CpG Reverse

GGCGTCCCAGTCTCAGCACAAA

62

CGGTTCCTTCCTGCGCCTTTATCT

61.2

GA2CpG Reverse v2
GA4CpG Forward v3
GA4CpG Reverse v3
GB1CpG Forward v2
GB1CpG Reverse v2
GNPDA2CpG Forward

Table 3.1. Primer sequences for DNA methylation studies.
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percentage of unmethylated DNA and methylated DNA using the following equations,
where F is the fraction of DNA evaluated:
DNA refractory to enzyme digestion:

Unmethylated DNA:

Hypermethylated DNA:

Intermediately methylated DNA:

Percentages were averaged among groups, standard error was calculated, and a
Student’s T-test was used to analyze significance between the percentage of total
methylation between groups.

Results
De novo DNA methylation of the CpG island of the GABRA2 promoter has been
shown to occur in both schizophrenia and aging (Siegmund, Connor et al. 2007,
Rukova, Staneva et al. 2014), possibly suggesting that DNA methylation at this locus
can vary based on genetic variation and developmental processes. To evaluate the
possible presence of DNA methylation at the GABRA2 promoter, we used a DNA
methylation assay which uses a methylation sensitive enzyme (HhaI), a methylation
dependent enzyme (McrBC), and a double digest with both enzymes (see methods for
further explanation). Digestion is followed by qPCR and Ct values are used to calculate
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the percentage of unmethylated and methylated DNA. For example, if the target region
is methylated, the Ms digest will result in little to no degradation of template resulting in
qPCR Ct values equal to the mock digest, while the majority of the template will be cut
by the Md enzyme resulting in an increase in Ct value.
We first examined fibroblast DNAs to evaluate CpG methylation status at the
GABRA2 promoter CpG island site. We had hypothesized that non-expresser
fibroblasts possessed DNA methylation at the GABRA2 promoter and that this was
potentially maintained during the reprogramming process. Unexpectedly, we found that
in dermal fibroblasts the GABRA2 promoter CpG island was unmethylated in all lines
tested, regardless of GABRA2 tag-SNP genotype or expression phenotype (Figure
3.2A). After the reprogramming process, iPSC clones generated from the same
fibroblasts became differentially methylated (Figure 3.2B, the two iPSC clones colorcoded to parental fibroblast strain) indicating that reprogramming was inducing DNA
methylation at this site, and that the level of methylation could differ between individual
iPSC clones generated from the same fibroblast line. Further, there were discordant
iPSC clones from the same parental fibroblasts. One such example is the CC line 703
(pink dots), which gave rise to one CpG hypermethylated clone and one unmethylated
clone. Discordance among clones was also seen in chromosome 4p12 GABAA receptor
subunit gene expression status in iPSC-derived neurons (Lieberman, Kranzler et al.
2015).
While the sample size in Figure 3.2B is small, there is a noticeable difference
between TT lines, where only one of six clones shows greater than 80% CpG
methylation at this site, and C-carrier lines where six out of eight have greater than 80%
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Figure 3.2. DNA methylation at the CpG island in the GABRA2 promoter. (A) DNA methylation in
fibroblasts in all three GABRA2 rs279858 genotypes. Fibroblasts give rise to both expresser and nonexpresser iPSC lines. (B) Two iPSC lines generated from each of the fibroblasts from A. Graph shows
varying levels of DNA methylation at the GABRA2 CpG island among clones from the same fibroblast
line. Parental fibroblasts are color coded to their resulting iPSC clones.
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methylation at this site. This suggests that there is potentially some relation of CpG
methylation to genotype. To evaluate the potential difference between expresser and
non-expresser lines, 24 expresser lines and 16 non-expresser lines were analyzed.
From this, we found that GABRA2 promoter CpG island methylation was greater in
iPSC lines whose neural products were non-expressers, compared with expresser iPSC
lines (Figure 3.3) (75% vs. 43%, respectively; *p=0.02).
To see if this difference in DNA methylation between expresser and nonexpresser lines was specific to the GABRA2 CpG island, or might be present for other
GABAA receptor subunit genes on chromosome 4p12, we also examined sites within
the CpG islands of the GABRA4 and GABRB1 promoters. The GABRG1 promoter does
not contain an annotated CpG island and therefore was not examined. Similar to
GABRA2, non-expresser lines showed more DNA methylation at the CpG islands in
both the GABRA4 (**p=0.01) and GABRB1 (***p=0.003) promoters (Figure 3.4A, B).
Based on the histone modification data in Chapter 2 and the gene expression data
published in Lieberman et al 2015, we predicted that this variation in CpG methylation
would be localized to the GABAA cluster genes so we targeted a site in the CpG island
in the promoter of a flanking gene, GNPDA2. We observed low levels of methylation for
GNPDA2 (Figure 3.4C); 0.04% +/- 0.01% expresser (n=2); 16.83% +/- 16.59% nonexpresser (n=3) and no significant difference between expressers and non-expresser
lines (p=0.4) at this site suggesting that this difference in DNA methylation is specific to
the GABAA receptor subunit gene cluster on chromosome 4p12.
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Figure 3.3. DNA methylation in iPSCs targeting a site in the CpG island in the promoter of GABRA2.
Non-expresser lines had significantly more DNA methylation than expresser lines (expresser n=24
and non-expresser n=16; *p=0.02).
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Figure 3.4. DNA methylation in expresser and non-expresser iPSCs. Percent DNA methylation at sites
within the CpG island in the GABRA4 promoter (expresser n=8 and non-expresser n=7; **p=0.01) (A),
the CpG island in the GABRB1 promoter (expresser n=5 and non-expresser n=5; ***p=0.003) (B), and
the CpG island in the promoter of a flanking gene of the GABAA receptor subunit gene cluster, GNPDA2
(expresser n=2 and non-expresser n=3; p=0.42) (C).
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Discussion
It is known that the reprogramming process can result in aberrant side effects
including changes in DNA methylation that are probably intrinsic to correct
reprogramming (Lister, Pelizzola et al. 2011, Liang and Zhang 2013). However, for the
lines evaluated in this thesis, this does not seem to be a random phenomenon. We
found that DNA methylation at the GABRA2 gene promoter in iPSCs is significantly
related to the future chromosome 4p12 GABAA receptor subunit gene cluster
expression status in neural cells. It is possible that the DNA methylation differences
dissipate after sufficient passages; however, there were no noticeable changes in
methylation of lines in early passages versus the same lines at later passages (data not
shown). In addition, preliminary studies with neuroepithelial cells show maintenance of
the DNA methylation status reflecting the iPSC line used (data not shown).
One thing we do not know, however, is whether the DNA methylation we are
seeing in the lines is coming from the AUD risk C-allele, the T-allele, or both. Allelic
discrimination assays done in Lieberman et al. 2015 looking at SNPs in GABRG1,
GABRA4, and GABRB1 suggest there is some allelic bias in gene expression in this
region. This could mean there is also bias in DNA methylation, especially since DNA
methylation is related to gene expression, or rather, repression.
A possible explanation of this increased DNA methylation at the GABRA2 CpG
island in non-expresser lines could be that the functional variant(s) associated with the
tag-SNP rs279858 cause an increase in DNMT3A/B activity causing de novo DNA
methylation. Because only one amplicon at each CpG island was evaluated, it is
unknown if this is specific to the chromosome 4 GABAA receptor subunit gene cluster or
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if there is a more global phenomenon in these lines. To test this, full genome
sequencing after a methyl-ChIP pull-down could be used to examine this.
Another interesting point with these findings is that while we saw methylation
differences between expressers and non-expressers, when the methylation data were
grouped according to rs279858 genotype, there was a trend, but no significant
differences (data not shown). This would suggest that the initial DNA methylation
generated during reprogramming is random with respect to rs279858 tag-haplotype, but
that the maintenance of the DNA methylation states may be biased toward the loss of
methylation during neural differentiation in rs297858 TT lines and maintenance of
GABRA2 CpG methylation in CC lines. This would predict an association of methylation
with genotype in neural cells, which had previously been associated with expression
phenotype.
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Chapter 4.
Discussion and Future Directions

Discussion
Chapter 1 presented an interesting phenotype seen when studying an AUD
associated SNP in the GABRA2 gene using iPSC-derived neural cell cultures.
Lieberman et al., 2015, showed that lines derived from subjects carrying the rs279858
AUD risk C-allele showed decreased expression of a cluster of GABAA receptor subunit
genes on chromosome 4p12; GABRG1, GABRA2, GABRA4, and GABRB1 were
termed “non-expresser” lines. They also found that the flanking genes of this cluster
were expressed in both expresser and non-expresser lines. Because this phenotype
was seen exclusively in this cluster of GABAA receptor subunit genes on chromosome
4p12, we hypothesized that they share a common epigenetic regulatory element.
In Chapter 2, we explored the idea that the cluster of GABAA receptor subunit
genes on chromosome 4p12 was being regulated by changes in histone modifications
within this region. We looked at two modifications, one associated with active chromatin,
H3K4me3, and one associated with transcriptional repression, H3K27me3. Using ChIP
followed by genome-wide sequencing and qPCR, we found significant differences
between expresser and non-expresser lines not only in iPSC-derived neurons, but also,
and perhaps unexpectedly, in iPSCs. While previous ChIP-seq data from the UCSC
Genome Browser indicated a poised promoter in iPSCs and ES cells, we did not see
expression of the H3K4me3 mark in non-expresser lines indicating not a poised gene,
but a repressed one.
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There is a known correlative relationship between the H3K27me3 mark and DNA
methylation as they are both marks for repression, and a known inverse relationship
between the H3K4me3 mark and CpG island DNA methylation (Cedar and Bergman
2009). In Chapter 3, we set out to elucidate possible differences in DNA methylation at
CpG islands in the promoters of the GABAA receptor subunit genes on chromosome
4p12. We found that non-expresser lines showed significantly higher average DNA
methylation compared to expresser lines, which were largely unmethylated. Only five of
24 lines were >80% methylated in expresser lines versus 11 of 16 in the non-expresser
lines. The fact that we see not only a reduction in H3K4me3 enrichment in nonexpresser lines, but also increased DNA methylation of the GABAA receptor subunit
gene CpG islands, is consistent with the idea that histone methylation of H3K4 inhibits
DNA methylation at CpG islands.
During differentiation, when promoters change from a poised state and begin to
shift to either an active promoter or repressed, there can also be changes in the types of
histone modifications present. The repressive H3K27me3 mark is common in pluripotent
cells and is common in development, whereas the repressive H3K9me3 mark is
associated with differentiated cells and is a more stable repressive mark. One possibility
is that the H3K27me3 mark has been replaced by the H3K9me3 mark in the nonexpresser lines so we are missing a key repressive mark, which will be looked at in
future studies.
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Future Directions
An alternative regulatory mechanism not explored in this research may involve
the rs279858 SNP itself. This synonymous SNP changes a TTT-lysine into a TTClysine, with virtually no codon preference in humans. While previously thought of as
“silent mutations,” GWAS studies have consistently shown synonymous SNPs
correlated to many illnesses (Plotkin and Kudla 2011). Though there is no real codon
preference here, the reason for this expresser versus non-expresser phenotype could
be linked to the change in codon itself. Changing the codon has been shown to adjust
the mRNA structure, potentially leaving it less or more stable as a result, thus affecting
protein generation, or protein structure and folding (Plotkin and Kudla 2011). However,
based on our findings here, it would seem that this is not the case. It seems that there is
in fact a functional variant yet to be discovered that is influencing the creation of histone
modification profiles and DNA methylation in iPSCs.
While expresser and non-expresser status has been linked to rs279858 genotype
as reported in Lieberman et al. 2015, there are outliers present. The trend is that TT
homozygotes are expressers and that C-carriers are non-expressers. However, there
are cases where a CT or CC subject can produce both an expresser line and a nonexpresser line. In addition there are two TT subjects which produce non-expresser iPSC
lines. This suggests that we are close to the functional variant, but that it is not directly
linked to rs279858 genotype. However, using the tag-SNP rs279858 as a marker that
we see is linked to epigenetic features like DNA methylation of CpG islands, we can use
this SNP and this assay to screen additional lines in the future.
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In addition, the findings in this study could be relevant on a greater scope. If we
are seeing such a dramatic phenotype in iPSC lines with different genotypes at this one
SNP, it is possible similar phenotypes exist in iPSCs from other illnesses. It is possible
that other SNPs associated with other illnesses are also somehow indirectly influencing
DNA methylation of CpG islands, or histone modifications as were associated with the
rs279858 genotype.
Considering the fact that we see such a strong phenotype in iPSCs and in the
early development of neurons, the effects that this phenotype might have in the
developing brain are of interest. Perhaps this phenotype only occurs in regions linked to
AUDs such as the frontal cortex and the reward pathway including the ventral tegmental
area and the nucleus accumbens. This would lead to a change in the normal pattern of
GABAA subunit utilization within these regions with different electrophysiological
characteristics and subtle variation and result in the disruption of

these neuronal

systems.

Long distance chromatin looping
Another possible epigenetic feature is long distance chromatin looping. In
addition to transcription factors binding promoters of genes, chromatin can also be
looped bringing a regulatory element, such as an enhancer, into close proximity to a
promoter affecting overall transcriptional output of the gene. A common protein that
initiates long distance chromatin looping is the CCCTC-binding factor (CTCF), a 11-zinc
finger protein. CTCF binds a specific sequence in the genome, CCCTC, and with the
help of cohesin (DeMare, Leng et al. 2013, Merkenschlager and Odom 2013), CTCF
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proteins can loop together bringing distant regulatory elements, such as enhancers, in
close contact with promoters creating an active chromatin hub. This leads to higher
levels of transcription (Figure 4.1; adapted from (Stadhouders, Thongjuea et al. 2012)).
Based on ChIP-seq data (from the UCSC Genome Browser) done with an antibody to
CTCF in iPSCs, there are multiple CTCF sites in and around the GABAA receptor
subunit gene cluster on chromosome 4p12. One way to look at the 3D structure of these
loops, and to see which sites interact with which, is to use Chromatin Conformation
Capture (3C). This process involves crosslinking cells, digesting the DNA, ligating the
ends together, and reverse crosslinking. The products are then detected by PCR, and
the quantified products are mapped to the genome and interactions can be visualized
based on a known anchor site to other distant sites (Naumova, Smith et al. 2012). A
variation of this called Chromatin Interaction Analysis by Paired-End Tag sequencing, or
ChIA-PET, uses this technique combined with immunoprecipitation. For example,
studies done by Ruan et al., (2012) as part of the ENCODE project, used ChIA-PET in
K562 cells to visualize long-distance chromatin looping between CTCF sites. The data
from these studies indicate a possible loop encompassing the chromosome 4p12
GABAA receptor subunit gene cluster (Figure 4.2). It is possible that the functional
SNP(s) linked to the tag-SNP rs279858 change an anchor point or distal point for long
distance chromatin looping.

Targeted resequencing
The goal of this research is to aid in finding the functional genetic variant(s)
within the GABRA2 haplotype block associated with AUDs. In order to do so, our lab
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Figure 4.1. CTCF looping. CTCF binds a specific sequence in the genome and with the help of cohesin,
CTCF proteins loop together bringing elements, such as enhancers, in close contact of promoters
creating an active chromatin hub. This leads to higher levels of transcription (Figure adapted from
Stadhouders, Thongjuea et al., 2012).
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Figure 4.2. ChIA-PET from the UCSC Genome Browser looking at long distance chromatin looping initiated by CTCF in K562 cells. The red box
encompasses the GABAA receptor subunit gene cluster on chromosome 4p12. The blue star represents a possible CTCF anchor site. The
other two yellow stars show CTCF binding sites that the anchored CTCF may interact with. This suggests there is a short loop and a longer loop
present in this region.

has done some targeted resequencing of the 140kb haplotype block using the Haloplex
system. We looked at three TT and three CC expressers, and one TT and two CC nonexpressers. While we did not find any SNPs associated with expression status stronger
than the tag-SNP rs279858, we did find 224 SNPs in linkage disequilibrium with
rs279858. In addition, we found a ~2kb deletion in the intergenic region between
GABRA2 and GABRG1 in TT subjects, regardless of chromosome 4p12 GABAA
receptor subunit gene cluster expression status (Figure 4.3). Data from the 1000
Genomes Project shows this deletion present in approximately 47% of Caucasian
chromosomes. It is possible that CC subjects, which do not have this ~2kb deletion,
have a sequence within this region prone to altering regional epigenetics, which
ultimately influences the expression of the chromosome 4p12 GABAA receptor subunit
genes. In fact, there is a THE1B long terminal repeat (LTR) sequence within this
deletion, which has previously been shown to activate the proto-oncogene CSF1R in
human lymphoma cells (Lamprecht, Walter et al. 2010). The activation of this LTR could
potentially be recruiting DNMTs to this region of the genome, or be inhibiting methylation
of H3K4 in non-expresser lines during neural differentiation.
Intriguingly, the frequency of this deletion is seen far less in African Americans,
affecting only 22% of chromosomes and is not linked to rs279858, making these
subjects an asset to finding the possible functional variant in this haplotype block. We
have obtained ten African American fibroblast lines and genotyped them (Table 4.1).
There is one line of particular interest as it is homozygous for TT at the rs279858
genotype. As mentioned above, Caucasian lines homozygous for TT also contain a
~2kb deletion in the intergenic region between GABRA2 and GABRG1, this line,
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563
727
556
728
739
740
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Figure 4.3. Targeted resequencing pile-up data of the region spanning the 140kb haplotype block (3’
end of GABRA2 and the intergenic region between GABRA2 and GABRG1. TT lines show a 2kb
deletion in this region, regardless of expression status.
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Line

rs279858

2kb INDEL

CD2

CT

DEL/INS

CD3

TT

INS/INS

CD4

CT

INS/INS

CD5

CT

INS/INS

AG14298

CT

DEL/INS

GM03349C

TT

DEL/INS

AG09699

TT

DEL/DEL

AG09555

TT

DEL/DEL

AG09150B

TT

DEL/DEL

GM05757C

CT

DEL/INS

Table 4.1. African-American fibroblast lines with corresponding rs279858 genotype and the presence of
a 2kb insertion/deletion in the intergenic region between GABRA2 and GABRG1. The highlighted line is
of particular interest.
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however, does not have this deletion (highlighted line in Table 4.1). These lines will be
reprogrammed into iPSCs by the UConn Stem Cell Core, and future studies will look at
the histone modification profiles and DNA methylation pattern at CpG islands of these
lines, and mRNA expression of GABAA receptor subunits genes will be measured in
iPSC-derived neurons.

Targeted editing with CRISPR/Cas9
The clustered regularly interspaced short palindromic repeats (CRISPR) and the
CRISPR associated protein 9 (Cas9) (CRISPR/Cas9) system is based on an adaptive
immune response against microphages in prokaryotes and is the newest genome
editing tool first used in mammalian cells in 2013 (Hsu, Lander et al. 2014). A single
guide RNA (sgRNA), composed of a CRISPR RNA (cRNA) fused to a trans-activating
cRNA (tracrRNA) can be engineered to target a specific sequence in the genome where
the Cas9 nuclease creates a double-stranded break allowing the genome to be edited
at this site (Ceasar, Rajan et al. 2016). By utilizing this technology, it is possible to
efficiently target and modify genetic mutations that cause disease. For example, when
we discover candidates for the functional variant linked to our tag-SNP rs279858, we
can use the CRISPR/Cas9 system to target and edit this variation in non-expresser
lines to create isogenic versions of the previously deemed ‘non-expresser’ lines. By
doing this, we should see changes in DNA methylation and histone modification
enrichment at the promoters of the chromosome 4p12 GABAA receptor subunit gene
cluster in iPSCs, and gene expression of the chromosome 4p12 GABAA receptor
subunit gene cluster in neurons.
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Alternatively, we could use the CRISPR/Cas9 system to find the functional
variant. As mentioned above, our targeted resequencing of the 140kb haplotype block
uncovered a 2kb deletion seen in the TT lines, regardless of expression status, that the
CC lines did not possess. It was also mentioned that there is a THE1B sequence within
this sequence that could potentially be creating the expresser and non-expresser lines.
We could use CRISPR/Cas9 to target and this sequence in CC lines to see if DNA
methylation decreases, histone modification enrichment at the promoters of the
chromosome 4p12 GABAA receptor subunit gene cluster increases in iPSCs, and gene
expression of the chromosome 4p12 GABAA receptor subunit gene cluster in neurons is
restored.

Allelic imbalance
While once thought to be limited to X-linked and imprinted genes, recent studies
have found that many autosomal genes also show monoallelic expression (Nag, Savova
et al. 2013). In the recent publication from the lab, Lieberman et al., 2015, showed
allelic imbalance in a subset of lines looking at iPSC-derived neural culture cDNA at
SNPs in genes nearby rs279858 (Lieberman, Kranzler et al. 2015).
We found a SNP located in a H3K4me3 enriched region of the GABRA4
promoter, rs2229940. In a preliminary experiment, we used a TaqMan genotype assay
targeting this SNP with ChIP DNA from H3K4me3 and H3K27me3 immunoprecipitations
to look at the presence of allelic imbalance of histone modification enrichment in this
GABAA receptor subunit gene cluster. Though inconclusive, preliminary results suggest
the presence of possible allelic bias suggesting there is random event that shows allelic
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preference during reprogramming, that is possibly influenced by a functional variant in
the 140kb haplotype block.
In addition to possible allelic bias of histone modifications, it is also unknown if
the DNA methylation we are seeing is coming from only one allele, or a combination of
the two. Using digested DNA from the DNA methylation assays, allelic imbalance assay
can be done to assess allelic imbalance of DNA methylation in fibroblasts and iPSCs.

Comparing iPSCs to hESCs
We found a significant difference in DNA methylation at the CpG island in the
GABRA2 promoter depending on rs279858 genotype. An interesting experiment would
be to look at DNA methylation at the CpG island in the GABRA2 promoter as well as
H3K4me3 and H3K27me3 enrichment in human embryonic stem cell (ESC) lines.
Looking at hESC lines would shed light on whether what we are seeing in iPSCs is an
actual developmental difference linked to rs279858 genotype, or an effect of
reprogramming skin cell fibroblasts into iPSCs. Preliminary data in our lab has looked at
DNA methylation at the GABRA2 CpG island in five ESC lines. Among the lines were
H1 (CC genotype), H9 (TT), CT2 (TT), CT3 (CT), and CT4 (TT). While the sample size
was small, we saw no significant correlation to rs279858 genotype to DNA methylation,
as most lines, regardless of genotype were unmethylated. This would suggest that what
we are seeing in the iPSC lines is due to an event occurring during the reprogramming
process. It is known that many aberrant effects can take place during reprogramming,
such as random mutations, DNA methylation, and changes in histone modification
profiles. However, even if what we are seeing is a reprogramming side effect, we have
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shown that it is significantly related to rs279858 genotype indicating some link between
genotype and epigenetic regulation. Further studies should be done to look at more
hESC lines to see if this is a pluripotent stem cell phenomenon, or a reprogramming
artifact cued by the functional variant linked to the rs279858 genotype.

Working model
The findings in this thesis have provided insights into the epigenetic factors
affecting gene expression in iPSC-derived neural cultures from lines with different
rs279858 genotypes. Based on these findings, we have established a working model
(Figure 4.4). This model suggests that fibroblasts with different rs279858 genotypes
have no epigenetic differences between lines. However, during the reprogramming
process, placement of H3K4me3 marks and de novo DNA methylation at the CpG
islands of the chromosome 4p12 GABAA receptor subunit gene cluster differs creating
expresser lines and non-expresser lines. As mentioned in Chapter 3 discussion, there
were no significant differences in the amount of DNA methylation between genotypes,
but there were significant differences between expressers and non-expressers. This
could indicate that the initial DNA methylation during reprogramming is random, but the
maintenance of this methylation could differ between genotypes. The absence of
H3K4me3 in non-expresser lines also provides an opportunity for the CpG islands in
this region to be methylated. Then when iPSCs are differentiated into neurons, the DNA
methylation resolves and is either present (in non-expresser lines) or absent (in
expresser lines).

75

Fibroblasts
No DNA Methylation
No H3K4me3 enrichment

iPSCs
Expressers

Non-expressers

5/24 >80% methylation
H3K4me3 enrichment

11/16 >80% methylation
No H3K4me3 enrichment

DNMT recruitment?

Neurons

?

0/24 >80% methylation
H3K4me3 enrichment

?

TT associated

16/16 >80% methylation
No H3K4me3 enrichment
C-Carrier associated

Figure 4.4. Working model.
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Our revised hypothesis is that the yet-to-be-identified functional variant inhibits
long distance chromatin looping, inhibits H3K4 methylation, and/or recruits DNMT3A
and DNMT3B for de novo DNA methylation, resulting in repression of this region.

Conclusion
This research provides a small entrée into understanding the epigenetic changes
seen in iPSCs after reprogramming and how they may regulate and affect gene
expression in later development, especially as it relates to AUDs. Research models are
never perfect or completely applicable, and the use of iPSCs in researching
neurological illnesses certainly has its limitations. However, IPSCs and iPSC-derived
neurons have provided a new unparalleled way to study neurological illnesses. They
have given us access to live human neurons and allowed us to study the
electrophysiological, morphological, and molecular phenotypes previously unknown.
Now that we have the tools to study AUDs at a cellular and molecular level, we can
focus on more specific elements of why certain SNPs increase the risk of developing an
AUD.
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